menu
    • menu
    [{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Lytix Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||peptides","graph1":"Oncology","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Oslo University Hospital \/ Lytix Biopharma","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ Lytix Biopharma"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Ruxotemitide","moa":"||Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biopharma \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Ruxotemitide","moa":"||Cell death","graph1":"Oncology","graph2":"Phase I","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Lytix Biopharma \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Lytix Biopharma \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"Lytix Biopharma","sponsor":"LabCorp | OWL","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||peptides","graph1":"Oncology","graph2":"Phase II","graph3":"Lytix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lytix Biopharma \/ LabCorp | OWL","highestDevelopmentStatusID":"8","companyTruncated":"Lytix Biopharma \/ LabCorp | OWL"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Instat Clinical Research | HeartcoR Solutions | Myonex | Vial","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"||peptides","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verrica Pharmaceuticals \/ Instat Clinical Research | HeartcoR Solutions | Myonex | Vial","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Instat Clinical Research | HeartcoR Solutions | Myonex | Vial"}]

    Find Clinical Drug Pipeline Developments & Deals for Ruxotemitide

    Menu

    Ruxotemitide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oslo University Hospital

                            Country arrow
                            EPSC
                            Not Confirmed

                            Oslo University Hospital

                            Country arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxotemitide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Lytix Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 21, 2024

                            Lead Product(s) : Ruxotemitide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Lytix Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Verrica Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Verrica Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verrica Announces Positive Results for Phase 2 Study of VP-315 in Basal Cell Carcinoma

                            Details : VP-315 (ruxotemitide)is a potential first-in-class oncolytic peptide to induce immunogenic cell death. It is under phase 2 clinical development for the treatment of Basal Cell Carcinoma.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            August 14, 2024

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Verrica Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Verrica Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verrica Doses Last Patient in Phase 2 Study Of VP-315 for Skin Cancer

                            Details : VP-315 (ruxotemitide) is an oncolytic peptide immunotherapy in Phase 2, aiming to treat basal cell carcinoma by inducing immunogenic cell death.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 01, 2024

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Verrica Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Verrica Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for...

                            Details : VP-315 (ruxotemitide, formerly known as LTX 315) is a potential first-in-class oncolytic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death, which may offer a non-surgical option for patients suffering from skin can...

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            December 04, 2023

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lytix Biopharma

                            Norway arrow
                            EPSC
                            Not Confirmed

                            Lytix Biopharma

                            Norway arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxotemitide,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lytix Biopharma AS Announces that an Abstract on LTX-315 in Combination With Adoptive Cell Therapy Is Selected...

                            Details : The trial demonstrated that combination of LTX-315 and ACT is feasible and tolerable, and that CD4+ and CD8+ T cells can be expanded in vitro from STS that have been pretreated with the oncolytic molecule LTX-315.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 27, 2022

                            Lead Product(s) : Ruxotemitide,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lytix Biopharma

                            Norway arrow
                            EPSC
                            Not Confirmed

                            Lytix Biopharma

                            Norway arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Verrica Pharmaceuticals

                            Deal Size : $111.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lytix Biopharma Receives Milestone Payment From Verrica Pharmaceuticals Inc. Triggered by First Patient Dosed ...

                            Details : Verrica, has an exclusive license agreement with Lytix to develop and commercialize LTX-315 for skin cancer conditions. LTX-315 is a first-in-class oncolytic peptide derived from human lactoferrin, with potential lytic and immunostimulating activities.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            May 04, 2022

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Verrica Pharmaceuticals

                            Deal Size : $111.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Verrica Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Verrica Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class ...

                            Details : LTX-315, a potential first-in-class oncolytic peptide directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to surgery, for the treatment of basal cell carcinoma.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 04, 2022

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lytix Biopharma

                            Norway arrow
                            EPSC
                            Not Confirmed

                            Lytix Biopharma

                            Norway arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxotemitide,Tumor Infiltrating Lymphocyte

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lytix Biopharma to Present at the American Society of Clinical Oncology (ASCO) Annual Meeting

                            Details : LTX-315 is a potential first-in-class oncolytic molecule administered directly into a tumor to induce immunogenic cell death, which also has demonstrated positive tumor-specific immune cell responses in multi-indication Phase I/II oncology trials.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 28, 2022

                            Lead Product(s) : Ruxotemitide,Tumor Infiltrating Lymphocyte

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Verrica Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Verrica Pharmaceuticals

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Instat Clinical Research | HeartcoR Solutions | Myonex | Vial

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            January 12, 2022

                            Lead Product(s) : Ruxotemitide,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Instat Clinical Research | HeartcoR Solutions | Myonex | Vial

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lytix Biopharma

                            Norway arrow
                            EPSC
                            Not Confirmed

                            Lytix Biopharma

                            Norway arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ruxotemitide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : LabCorp | OWL

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 12, 2021

                            Lead Product(s) : Ruxotemitide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : LabCorp | OWL

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth